XSHE
300636
Market cap445mUSD
Oct 09, Last price
7.16CNY
1D
0.85%
1Q
7.35%
IPO
19.96%
Name
Jiangxi Synergy Pharmaceutical Co Ltd
Chart & performance
P/E
41.14
P/S
3.64
EPS
0.17
Div yield, %
0.56%
Shrs. gr., 5y
4.46%
Rev. gr., 5y
6.91%
Revenues
827m
+8.96%
Net income
73m
-31.42%
CFO
202m
-29.02%
Dividend
Jun 03, 20260.04 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Yichun, People's Republic of China, Jiangxi Synergy Pharmaceutical Co., Ltd. was established in 2004. The company specializes in the global production and sale of active pharmaceutical ingredients (APIs), as well as liquid crystal compounds and various chemical intermediates.
Key people
Jinqiao Hu
Finance Director · since 2015
Zhengwei Pang
Chairman of the Board, General Manager · since 2005
Chih-Cheng Chou
Deputy General Manager, Secretary of the Board · since 2015
Guojun Huang
Deputy General Manager, Director · since 2015
Huigang Jiang
Director · since 2018
Yuansen Jiang
Deputy General Manager, Director · since 2011
Chung Shing Leung
Vice Chairman of the Board, Deputy General Manager · since 2011
Xiaohua Wang
Director · since 2017
Independent Director · since 2015
Dingdai Peng
Independent Director
Chuyi Yu
Independent Director · since 2015
Headquarters & legal address
江西省宜春市奉新县工业园区
宜春市, JX 330700
CN
宜春市, JX 330700
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||